MAPK3 and cancer: Interestingly, evidence from studies on cancers and GBM cell lines discusses the fact that metformin could disrupt the insulin signaling pathway in cancerous cells by downregulating key signaling molecules in this pathway, such as PI3K, Akt, and ERK1/2.